Purchase this article with an account.
Jeeyun Ahn, Sunyoung Park, Hyuncheol Kim, Ji Hyun Park, Ji Yeon Park, Duck Jin Hwang, Seong Joon Ahn, Yong-Kyu Kim, Kyu Hyung Park, Se Joon Woo; Intraocular pharmacokinetics of bevacizumab and ranibizumab in vitrectomized versus non-vitrectomized rabbit eyes. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1080.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze intraocular pharmacokinetic properties of bevacizumab and ranibizumab in vitrectomized and non-vitrectomized rabbit eyes.
Twenty-five-gauge pars plana vitrectomy without lensectomy was performed in 35 rabbit eyes and 36 non-vitrectomized rabbit eyes served as control. Intravitreal injection of 1.25mg/0.05mL bevacizumab was performed in 17 vitrectomized (group 1-1) and 18 non-vitrectomized (group 1-2) eyes, respectively. Intravitreal injection of 0.25mg/0.025mL ranibizumab was performed in 18 vitrectomized (group 2-1) and 18 non-vitrectomized (group 2-2) eyes, respectively. Eyes were enucleated at 1 hour, 1, 2, 5, 14 and 30 days after the intravitreal injections and frozen at -80°C. Bevacizumab and ranibizumab concentrations in the vitreous and aqueous humor, as well as the retina/choroid, were determined using direct enzyme-linked immunosorbent assay.
Vitreous clearance of bevacizumab and ranibizumab showed distinct patterns, consisting of 2 phases and 1 phase, respectively. The vitreous half-life of bevacizumab and ranibizumab were 6.99, 7.06, 2.51 and 2.75 days in vitrectomized and non-vitrectomized eyes, respectively.
Vitrectomy did not substantially affect pharmacokinetic properties or chorioretinal concentrations of intravitreally injected bevacizumab or ranibizumab in rabbit eyes.
This PDF is available to Subscribers Only